2023 PREVIEW: THE ERA OF CHEAP MONEY IS OVER
The new year is upon us! What should biopharma companies and investors expect from 2023? Can they hope for better than 2022 or will it be more of the same? We already know the era of cheap money is over, but what else is afoot?
For a quick view of the data points that might define the year, we’ve whipped up an infographic with the highlights of our new 2023 Preview report.
Need more? Happy to help. You can find the full report here.